Specialty Derm

Discussion in 'Sun Pharma' started by anonymous, Jan 11, 2020 at 10:06 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The price manipulation through Foundation Care will get exposed.
    Ron and Tom have the greatest personal liability once the OIG comes in. AG too.
     

  2. anonymous

    anonymous Guest

    Ameluz is coming for us!! FYI here come some even bigger Odomzo expectations and a transition to Odomzo being 60% of our pay. The company needs a plan to make up lost revenue. We are their puppets, time to dance puppets, dance.
     
  3. anonymous

    anonymous Guest

    I am sooo glad that Iā€™m no longer a part of that circus. Incompetent people at best !
    #grassismuchgreener
     
  4. anonymous

    anonymous Guest

    How is Ameluz coming after us with no reps. They are bleeding cash and this shut down is not helping. The inflated 4th quarter numbers due to load in from a price increase mixed with the shutdown will mean no tubes in the 1st quarter. Ameluz is dead and Covid-19 was the final bullet
     
  5. anonymous

    anonymous Guest

    Really ?
    And Levulan had a great year, right ?
    #sticksdownagain
     
  6. anonymous

    anonymous Guest

    Sun did not furlough or layoff off their reps can Biofrontera say the same? Levulan hit the year goal. Look around and it will be easy to see who will win and who will be lucky if they could sell the shambles of the company that remains.
     
  7. anonymous

    anonymous Guest

    Just curious: are the VP of sales calling reps individually to check in?speciality and biologics? What do they have you all doing while WFH?